2026-06-14T03:40:55Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/184572024-11-28T15:16:33Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16966col_20.500.12105_16982col_20.500.12105_16990

00925njm 22002777a 4500 dc García-Alfonso, Pilar author Muñoz, Andrés author Jiménez-Castro, Jerónimo author Jiménez-Fonseca, Paula author Pericay, Carles author Longo-Muñoz, Federico author Reyna-Fortes, Carmen author Argilés-Martínez, Guillem author González-Astorga, Beatriz author Gómez-Reina, María José author Ruiz-Casado, Ana author Rodríguez-Salas, Nuria author López-López, Rafael author Carmona-Bayonas, Alberto author Conde-Herrero, Verónica author Aranda, Enrique author 2021-09-08 Trifluridine/tipiracil is currently approved for metastatic colorectal cancer (mCRC) refractory to available therapies. However, there is no consensus on factors that predict treatment outcomes in daily practice. We assessed the early clinical experience with trifluridine/tipiracil in Spain and potential survival markers. This was a retrospective cohort study of mCRC patients who participated in the trifluridine/tipiracil early clinical experience programme in Spain. The primary outcome was overall survival (OS). Associations between OS and patient characteristics were assessed using multivariate Cox regression analyses. A total of 379 patients were included in the study. Trifluridine/tipiracil was administered for a median of 3.0 cycles and discontinued mainly due to disease progression (79.2%). The median OS was 7.9 months, with a 12-month OS rate of 30.5%. Cox analyses revealed that the following variables independently enhanced OS: ≤2 metastatic sites, no liver metastasis, alkaline phosphatase < 300 IU, trifluridine/tipiracil dose reductions, and neutrophil/lymphocyte ratio < 5. Grade ≥ 3 toxicities were reported in 141 (37.2%) patients, including mainly afebrile neutropaenia (23.2%), anaemia (12.1%), and thrombocytopaenia (5.3%). This study supports the real-life efficacy and safety of trifluridine/tipiracil for refractory mCRC and identifies tumour burden, liver metastasis, alkaline phosphatase, dose reductions, and neutrophil/lymphocyte ratio as survival markers. 10.3390/cancers13184514 2072-6694 Cancers http://hdl.handle.net/10668/3928 34572740 http://hdl.handle.net/20.500.12105/18457 Biomarkers Chemotherapy Colorectal cancer Combination therapy Real-life Trifluridine/tipiracil Biomarcadores Quimioterapia Neoplasias colorrectales Quimioterapia combinada Trifluridina Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study